[go: up one dir, main page]

KR900701309A - 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법 - Google Patents

액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법

Info

Publication number
KR900701309A
KR900701309A KR1019900701395A KR900701395A KR900701309A KR 900701309 A KR900701309 A KR 900701309A KR 1019900701395 A KR1019900701395 A KR 1019900701395A KR 900701395 A KR900701395 A KR 900701395A KR 900701309 A KR900701309 A KR 900701309A
Authority
KR
South Korea
Prior art keywords
interferon
human
infection
administered
liquid nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019900701395A
Other languages
English (en)
Inventor
에이. 스마일즈 케네스
에이. 피이츠 에드윈
제이. 탠너 다니엘
Original Assignee
스테이나 브이. 칸스태드
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스테이나 브이. 칸스태드, 쉐링 코포레이션 filed Critical 스테이나 브이. 칸스태드
Publication of KR900701309A publication Critical patent/KR900701309A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

액체 질소 및 재조합 DAN사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 첨형 콘딜로마(Condylomata acuminata) 감염증의 각 병변에 유효량의 냉동외과용 제제를 투여란후, 각병변에 사람 α·인터페론의 유효량을 투여함을 특징으로 하여, 청형 콘딜로마 감염증의 치료를 요하는 환자를 치료하는 방법.
  2. 제1항에 있어서, 냉동외과용제제 (cryosurgical agent)가 액체 질소인 방법.
  3. 제1항 또는 제2항에 있어서, 사람 α인터페론이 재조합 사람 DNA 인터줴론 7·-2a 또는 r-2b인 방법
  4. 제1항 내지 제3항중 어느 한 항에 있어서, 사람 인터페론을 매주 3회 3주간 투여하는 방범.
  5. 제1항 내지 제4항중 어느 한 항에 있어서, 사람 α·인터페론을 병변내 주사로 투여하고 액체질소는 국소투여 하는 방법.
  6. 첨형 콘딜로마 감염증 환자에 사람 α·인터페론 및 냉동외과용제제를 투여하여 이 환자를 치료하는 혼용치료용 약제 제조를 위한 사람 α·인터페론의 용도.
  7. 냉동외과용 제제와 혼용으로 첨형 콘딜로마 감염증 환자를 치료하기 위한 사람 r인터궤론의 용도.
  8. 제6항 또는 제7항에 있어서. 사람 α인터페론이 재조합 사람 DNA 인터페론 α-2a 또는 α-2b인 용도.
  9. 사람 α인터페론 및 냉도외과용 제제를 첨형 콘딜로마 감염증 환자에 투여하여 치료하는 흔합 치료법에서 사용하기 위한 사람 α·인터페론을 포함함을 특징으로 하는, 약제학직 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900701395A 1988-11-01 1989-10-30 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법 Withdrawn KR900701309A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US265,612 1988-11-01
US07/265,612 US4959210A (en) 1988-11-01 1988-11-01 Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
PCT/US1989/004766 WO1990004977A2 (en) 1988-11-01 1989-10-30 Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon

Publications (1)

Publication Number Publication Date
KR900701309A true KR900701309A (ko) 1990-12-01

Family

ID=23011173

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900701395A Withdrawn KR900701309A (ko) 1988-11-01 1989-10-30 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법

Country Status (12)

Country Link
US (1) US4959210A (ko)
EP (2) EP0445145A1 (ko)
JP (1) JPH03503766A (ko)
KR (1) KR900701309A (ko)
AU (1) AU636312B2 (ko)
CA (1) CA2001884A1 (ko)
DK (1) DK79591A (ko)
IL (1) IL92161A0 (ko)
MY (1) MY106603A (ko)
PH (1) PH26680A (ko)
WO (1) WO1990004977A2 (ko)
ZA (1) ZA898234B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5165921A (en) * 1989-01-23 1992-11-24 National Geno Sciences, Inc. Method for treating condyloma acuminatum with interferon
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
AU9132091A (en) * 1990-12-21 1992-07-22 Schering Corporation Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
US6309662B1 (en) 1999-09-23 2001-10-30 Janet Buchanan Use of anti-inflammatory drugs for treatment of dermatological conditions
US7436227B2 (en) * 2003-05-02 2008-10-14 Silicon Laboratories Inc. Dual loop architecture useful for a programmable clock source and clock multiplier applications
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
RU2404743C2 (ru) * 2007-03-15 2010-11-27 Государственное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет Росздрава" Способ лечения аногенитальных бородавок
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
EP4019037A1 (en) 2017-03-31 2022-06-29 Accanis Biotech F&E GmbH & Co KG Prevention and treatment of non-melanoma skin cancer (nmsc)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) * 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4286690A (en) * 1979-03-05 1981-09-01 Commercial Management Corporation Escape device
JPS59175416A (ja) * 1983-03-25 1984-10-04 Sunstar Inc 皮膚および粘膜の角化異常治療用外用剤
CA1321347C (en) * 1986-11-10 1993-08-17 David C. Munch Human leukocyte interferon composition and skin treatment

Also Published As

Publication number Publication date
MY106603A (en) 1995-06-30
EP0445145A1 (en) 1991-09-11
DK79591D0 (da) 1991-04-30
EP0369632A1 (en) 1990-05-23
DK79591A (da) 1991-06-14
US4959210A (en) 1990-09-25
WO1990004977A3 (en) 1990-06-28
ZA898234B (en) 1990-07-25
PH26680A (en) 1992-09-15
CA2001884A1 (en) 1990-05-01
WO1990004977A2 (en) 1990-05-17
AU636312B2 (en) 1993-04-29
IL92161A0 (en) 1990-07-12
JPH03503766A (ja) 1991-08-22
AU4524689A (en) 1990-05-28

Similar Documents

Publication Publication Date Title
Maria et al. Botulinum toxin injections in the internal anal sphincter for the treatment of chronic anal fissure: long-term results after two different dosage regimens
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
AR019551A1 (es) Uso de la ribavirina en combinacion con el interferon alfa para la fabricacion de un medicamento para la terapia de combinacion para erradicar hcv-rna detectable en pacientes no afectados a tratamiento antiviral que tienen infeccion de hepatitis c cronica
BR9507189A (pt) Combinaçoes de proteinas tromboliticamente ativas e anticoagulantes e usos dos mesmos
KR900701309A (ko) 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
IL161889A (en) Use of omega interferon in the manufacture of a medicament for treating viral disease
KR910005858A (ko) 지방산 요법
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
PT92995A (pt) Metodo para o tratamento da disfuncao leucocita com gm-csf
KR960705578A (ko) 경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease)
ATE185274T1 (de) Therapeutisches mittel gegen drohenden abortus
KR960013383A (ko) 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
ES2211996T3 (es) Agentes de union a receptores de acido hialuronico y su uso para el tratamiento de tumores o de reestenosis.
ES2233101T3 (es) Dosis unitaria de fgf-2 angiogenicamente efectiva y su utilizacion.
KR900701322A (ko) 포도필린과 재조합 DNA인간 α인터페론의 배합물로 생식기 우췌를 치료하는 방법
KR960701657A (ko) 피부 상처 치료용 인자 XIII (Factor XIII for treatment of skin wounds)
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
KR910004186A (ko) 제약학적 배합물
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
BR0113115A (pt) Tratamento de hepatite c com timosina, interferon e ribavirina

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19900630

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid